RJA
GCVRZ

Raymond James & Associates’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Raymond James & Associates’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,893
Closed -$5K – 3843
2019
Q1 		$5K Sell
10,893
-122
-1% -$57 ﹤0.01% 3588
2018
Q4 		$5K Buy
11,015
+12
+0.1% +$6 ﹤0.01% 3492
2018
Q3 		$6K Buy
11,003
+19
+0.2% +$10 ﹤0.01% 3600
2018
Q2 		$5K Buy
10,984
+16
+0.1% +$7 ﹤0.01% 3553
2018
Q1 		$5K Sell
10,968
-100
-0.9% -$40 ﹤0.01% 3431
2017
Q4 		$4K Buy
11,068
+75
+0.7% +$28 ﹤0.01% 3401
2017
Q3 		$4K Hold
10,993
– – ﹤0.01% 3379
2017
Q2 		$4K Sell
10,993
-83
-0.7% -$34 ﹤0.01% 3320
2017
Q1 		$5K Sell
11,076
-17
-0.2% -$7 ﹤0.01% 3265
2016
Q4 		$4K Sell
11,093
-256
-2% -$87 ﹤0.01% 3215
2016
Q3 		$3K Sell
11,349
-35
-0.3% -$9 ﹤0.01% 3198
2016
Q2 		$3K Hold
11,384
– – ﹤0.01% 3003
2016
Q1 		$1K Buy
+11,384
New +$1.23K ﹤0.01% 2927

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Raymond James & Associates's GCVRZ Position: Q2 2019 in Review

Raymond James & Associates sold out of Sanofi Contingent Value Rights (GCVRZ) in Q2 2019, closing a stake of 10,893 shares — an estimated $5K sold.

Raymond James & Associates first reported a position in GCVRZ in Q1 2016 and held it in 13 quarters. The position peaked at $6K in Q3 2018. 104 funds tracked by Wall St. Rank hold GCVRZ as of Q2 2019.

  • Raymond James & Associates reported no remaining Sanofi Contingent Value Rights position as of Q2 2019 after selling out during the quarter.
  • Raymond James & Associates sold 10,893 Sanofi Contingent Value Rights shares in Q2 2019, an estimated $5K.
  • Raymond James & Associates first reported a position in Sanofi Contingent Value Rights in Q1 2016 and held it in 13 quarters.
  • Raymond James & Associates's Sanofi Contingent Value Rights position peaked at $6K in Q3 2018.
  • 104 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q2 2019.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.